latest news releases from the newsroom
Intellect Neurosciences, Inc.
Intellect Neurosciences to Participate in Rodman & Renshaw 2010 Annual Global Investment Conference in New York on September 14, 2010
NEW YORK, Sept. 1, 2010 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage trials to treat and prevent Alzheimer's disease (AD), has announced that Daniel G. Chain, Ph.D., the company's chief executive officer and chairman of the board, will speak at the Rodman & Renshaw Annual Global Investment Conference in New York City on September 14, 2010
Active Seniors Help Kick-Off Dallas Cowboys' 2010 Home Opener
DALLAS, Sept. 1, 2010 (GLOBE NEWSWIRE) -- Older adults from the Dallas/Ft. Worth area will hit the gridiron at Cowboys Stadium in Arlington on September 14 to help kick off the Dallas Cowboys' 2010 home schedule (the Cowboys host the Chicago Bears on September 19 after opening the season in Washington on September 12). More than 600 older adults are scheduled to participate in this special event, which will feature a SilverSneakers class demonstration. SilverSneakers is part of the nationally-acclaimed Healthways
Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics to Present at Rodman & Renshaw Conference in New York
DURHAM, N.C., Sept. 1, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) today announced that the company will present at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 14, 2010 at 10:25 AM EDT. The event is being held at The New York Palace Hotel. This presentation will be available via web cast at
Nabi Biopharmaceuticals Announces Long-Term Manufacturing Agreement With Diosynth RTP
ROCKVILLE, Md., Sept. 1, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced today that it has entered into a long-term commercial manufacturing agreement with Diosynth RTP, Inc. (Diosynth) for the manufacture of Drug Substance integral to the production of NicVAX, Nabi's innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse.